Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

Clinical trial NCT05576532 · UNKNOWN

Trial details

NCT number: NCT05576532
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

T-lymphoblastic Lymphoma Relapsed Disease Refractory Lymphoma Refractory Leukemia Safety Efficacy, Self

Start date: 2023-01-10
Primary completion: 2024-10-10
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.